Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEOGEN CORPNEOG · Entity 4338 | Senior Vice President | August 14, 2026 | August 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEOGEN CORP
Report date August 14, 2026 · Filed August 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,751 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Grant · Acquired 25,751 · Balance 25,751 F2: PSUs vest in total at the end of the three year anniversary date of the grant |
| Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.65 · Expires 2036-08-14 | Direct | 130,851 |
Reported balance
After 2026-08-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-14 · Grant · Acquired 130,851 · Balance 130,851 F1: Options vest in equal annual installments on each of the first three anniversary dates of the grants |
Filing footnotes · ownership attribution and instrument terms
F1: Options vest in equal annual installments on each of the first three anniversary dates of the grants
F2: PSUs vest in total at the end of the three year anniversary date of the grant
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
QUIDEL CORP /DE/
Report date May 27, 2022 · Filed June 01, 2022
Section 16 reporting ended · disclosed 2022-06-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 1
1 source rowRow 1 · 2022-05-27 · Disposition to issuer · Disposed 15,486 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $22.21 · Expires 2023-02-25 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-05-27 · Disposition to issuer · Disposed 3,194 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3: Vested in full. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $27.57 · Expires 2024-02-24 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-27 · Disposition to issuer · Disposed 6,360 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3: Vested in full. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $23.41 · Expires 2025-02-05 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-27 · Disposition to issuer · Disposed 3,910 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3: Vested in full. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $15.40 · Expires 2026-02-10 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-05-27 · Disposition to issuer · Disposed 1,954 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3: Vested in full. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $21.08 · Expires 2027-02-15 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-05-27 · Disposition to issuer · Disposed 1,349 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3: Vested in full. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $46.41 · Expires 2028-01-16 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-05-27 · Disposition to issuer · Disposed 3,455 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3: Vested in full. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $59.12 · Expires 2029-02-04 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-05-27 · Disposition to issuer · Disposed 3,020 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F4: 2,265 shares are vested in full; 755 shares will vest on February 4, 2023. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $77.16 · Expires 2030-02-03 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-05-27 · Disposition to issuer · Disposed 2,372 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F5: 1,186 shares are vested in full; the remaining 1,186 shares will vest in equal installments on February 3, 2023 and February 3, 2024. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $228.21 · Expires 2030-08-24 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-05-27 · Disposition to issuer · Disposed 1,906 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6: 476 shares are vested in full; 476 shares will vest on August 24, 2022; the remaining 954 shares will vest in equal installments on August 24, 2023 and August 24, 2024. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $254.00 · Expires 2031-02-01 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-05-27 · Disposition to issuer · Disposed 1,892 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F7: 473 shares are vested in full; the remaining 1,419 shares will vest in equal installments on February 1, 2023, February 1, 2024 and February 1, 2025. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $103.36 · Expires 2032-01-31 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-05-27 · Disposition to issuer · Disposed 4,957 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F8: 1,239 shares will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025;1,240 shares will vest on January 31, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2022-05-27 · Disposition to issuer · Disposed 1,510 · Balance 0 F9: Each restricted stock unit represents the right to receive one share of Quidel common stock. F10: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F11: 1,510 shares will vest on February 4, 2023. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2022-05-27 · Disposition to issuer · Disposed 1,186 · Balance 0 F9: Each restricted stock unit represents the right to receive one share of Quidel common stock. F10: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F12: 1,186 shares will vest in equal installments on February 3, 2023 and February 3, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2022-05-27 · Disposition to issuer · Disposed 591 · Balance 0 F9: Each restricted stock unit represents the right to receive one share of Quidel common stock. F10: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F13: 591 shares will vest in equal installments on August 24, 2022, August 24, 2023 and August 24, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2022-05-27 · Disposition to issuer · Disposed 1,420 · Balance 0 F9: Each restricted stock unit represents the right to receive one share of Quidel common stock. F10: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F14: 473 shares will vest on each of February 1, 2023 and February 1, 2024; 474 shares will vest on February 1, 2025. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2022-05-27 · Disposition to issuer · Disposed 4,958 · Balance 0 F9: Each restricted stock unit represents the right to receive one share of Quidel common stock. F10: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F15: 1,239 shares will vest on each of January 31, 2023 and January 31, 2024; 1,240 shares will vest on each of January 31, 2025 and January 31, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2022-05-27 · Disposition to issuer · Disposed 3,386 · Balance 0 F9: Each restricted stock unit represents the right to receive one share of Quidel common stock. F10: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F16: 1,693 shares will vest on January 31, 2024; 846 shares will vest on January 31, 2025; and 847 shares will vest on January 31, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho.
F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
F3: Vested in full.
F4: 2,265 shares are vested in full; 755 shares will vest on February 4, 2023.
F5: 1,186 shares are vested in full; the remaining 1,186 shares will vest in equal installments on February 3, 2023 and February 3, 2024.
F6: 476 shares are vested in full; 476 shares will vest on August 24, 2022; the remaining 954 shares will vest in equal installments on August 24, 2023 and August 24, 2024.
F7: 473 shares are vested in full; the remaining 1,419 shares will vest in equal installments on February 1, 2023, February 1, 2024 and February 1, 2025.
F8: 1,239 shares will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025;1,240 shares will vest on January 31, 2026.
F9: Each restricted stock unit represents the right to receive one share of Quidel common stock.
F10: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
F11: 1,510 shares will vest on February 4, 2023.
F12: 1,186 shares will vest in equal installments on February 3, 2023 and February 3, 2024.
F13: 591 shares will vest in equal installments on August 24, 2022, August 24, 2023 and August 24, 2024.
F14: 473 shares will vest on each of February 1, 2023 and February 1, 2024; 474 shares will vest on February 1, 2025.
F15: 1,239 shares will vest on each of January 31, 2023 and January 31, 2024; 1,240 shares will vest on each of January 31, 2025 and January 31, 2026.
F16: 1,693 shares will vest on January 31, 2024; 846 shares will vest on January 31, 2025; and 847 shares will vest on January 31, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2021 Filed Feb 5, 2021 18:49 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Exercise / conversionRestricted Stock Units · Derivative | 593 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008298 · doc4.xml · derivative · entry 3 Ranalli Tamara A. · CIK 0001822508 · SVP, Molecular Bus. Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,779 Underlying: Common Stock · 593 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 593 shares vested on the first anniversary date of the grant date, February 3, 2021. F4 · derivative.expiration_date: 593 shares vested on the first anniversary date of the grant date, February 3, 2021. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 18:49 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | Tax withholdingCommon Stock | 145 | $236.85 | $34,343.25 |
DisclosureSEC source: 0001209191-21-008298 · doc4.xml · nonDerivative · entry 2 Ranalli Tamara A. · CIK 0001822508 · SVP, Molecular Bus. Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,302 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 18:49 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantCommon Stock | 593 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008298 · doc4.xml · nonDerivative · entry 1 Ranalli Tamara A. · CIK 0001822508 · SVP, Molecular Bus. Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,447 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:46 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantNon-Qualified Stock Option · Derivative | 1,892 | $0.00 Strike: $254.00 | $0.00 |
DisclosureSEC source: 0001209191-21-007597 · doc4.xml · derivative · entry 2 Ranalli Tamara A. · CIK 0001822508 · SVP, Molecular Bus. Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,892 Underlying: Common Stock · 1,892 shares Expires 2031-02-01 F2 · derivative.exercise_date: One-quarter of the shares will vest annually over a four-year period, commencing on the first anniversary date of the grant date. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:46 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units · Derivative | 1,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-007597 · doc4.xml · derivative · entry 1 Ranalli Tamara A. · CIK 0001822508 · SVP, Molecular Bus. Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,893 Underlying: Common Stock · 1,893 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one (1) share of Quidel Corporation common stock. F2 · derivative.exercise_date: One-quarter of the shares will vest annually over a four-year period, commencing on the first anniversary date of the grant date. F2 · derivative.expiration_date: One-quarter of the shares will vest annually over a four-year period, commencing on the first anniversary date of the grant date. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 20:34 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantNon-Qualified Stock Options · Derivative | 1,906 | $0.00 Strike: $228.21 | $0.00 |
DisclosureSEC source: 0001209191-20-048478 · doc4.xml · derivative · entry 2 Ranalli Tamara A. · CIK 0001822508 · SVP, Molecular Bus. Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,906 Underlying: Common Stock · 1,906 shares Expires 2030-08-24 F3 · derivative.exercise_date: 476 shares will vest on the first anniversary date of the grant date, August 24, 2021; 476 shares will vest on the second anniversary date of the grant date, August 24, 2022; 477 shares will vest on the third anniversary date of the grant date, August 24, 2023; and 477 shares will vest on the fourth anniversary date of the grant date, August 24, 2024. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 20:34 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units · Derivative | 788 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-048478 · doc4.xml · derivative · entry 1 Ranalli Tamara A. · CIK 0001822508 · SVP, Molecular Bus. Unit 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 788 Underlying: Common Stock · 788 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F2 · derivative.exercise_date: 197 shares will vest on August 24, 2021; 197 shares will vest on August 24, 2022; 197 shares will vest on August 23, 2023; and 197 shares will vest on August 24, 2024. F2 · derivative.expiration_date: 197 shares will vest on August 24, 2021; 197 shares will vest on August 24, 2022; 197 shares will vest on August 23, 2023; and 197 shares will vest on August 24, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.